CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM proves its vigour

Cheplapharm successfully closes the first project with LEO Pharma

This week CHEPLAPHARM successfully closed the project with LeoPharma, which was started in June this year. It includes four off-patent brands which are well established by patients and prescribers equally - One-Alpha®, Pimafucin®, Locoid® and Zineryt®. The products are mainly focused on the therapeutic areas dermatology, gynaecology as same as calcium-metabolism. Cheplapharm therefore is able to expand its portfolio in various territories. The APIs of the referring products are Alfacalcidol, Hydrocortisone butyrate,  Natamycin and Erythromycin together with Zinc Acetate.

“We are very proud to show our competence in the partnership with a new partner, LEO Pharma. The acquired portfolio contains brands with a high quality and an excellent positioning, which will therefore strengthen our presence in these markets”, said CHEPLAPHARM´s CEO Sebastian F. Braun.


CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)

About LEO Pharma

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted dec-ades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

For more information about LEO Pharma, visit

Media contact:

LEO Pharma | Trine Juul Wengel - Global External Communication | tewdk(at)

Investor Relations topics

Back to top expand_less